BioSpace News Archive

StageZero Life Sciences, Ltd. today announced the availability of the BORDERPASS™ COVID-19 RT-PCR saliva test.

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, issued the following statement to stockholders.

Bolt Biotherapeutics (Nasdaq: BOLT), today announced the appointments of Brian O’Callaghan and Frank D. Lee to the Board of Directors.

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance marketplace, today announced that its management will present at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021 at 11:20 a.m. E.T.

Highly respected industry leaders including Ian Read, former CEO and Executive Chairman of Pfizer, and Clive Meanwell, Founder and former CEO of The Medicines Company, join Saama’s Board of Directors.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bulevirtide for injection (2 mg).

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved target enrollment in Study A of the Phase 2/3 CULTIVATE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate to severe Crohn’s disease (CD).

Datar Cancer Genetics Inc, a leading cancer research company focussed on early detection of cancers today announced that the US Food and Drug Administration (FDA) has granted ‘Breakthrough Device Designation’ for its ‘TriNetra™' blood test to detect early-stage Breast Cancer.

Simulations Plus, Inc. (Nasdaq: SLP), today announced that it has named Sharlene Evans, a proven executive with over 25 years of experience in operations, human resources, and personnel development, to the Company’s Board of Directors.